Joan is Managing Partner of Militia Hill Ventures, a business focused on building and growing high quality life sciences companies, and Chief Executive Officer of Spirovant, a gene therapy company with an initial focus on cystic fibrosis. Joan was also President and CEO of Azelon Pharmaceuticals, a venture-backed clinical stage company and President and CEO of Locus Pharmaceuticals, a computational chemistry discovery company. Prior to her role as CEO of Locus, Joan served in various leadership roles at Merck & Co, including roles in R&D drug development and business development. Dr. Lau also serves on various community and industry boards, including Talee Bio, the Alliance of Women Entrepreneurs (AWE) and the Human Rights Campaign.
Dr. Lau earned an MBA from the Wharton School of Business at the University of Pennsylvania, a PhD in Neuroscience from the University of Cincinnati College of Medicine and a BS in Bioengineering from the University of Pennsylvania.